一分钟看懂
这是一项关于非小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括S241656；FOLFOX6/FOLFOX7；FOLFIRI；Cetuximab；Panitumumab；Gemcitabine；Nab-paclitaxel，当前状态为招募中。登记地点显示中国北京、济南、上海、苏州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
S241656；FOLFOX6/FOLFOX7；FOLFIRI；Cetuximab；Panitumumab；Gemcitabine；Nab-paclitaxel · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- Shandong Cancer Hospital (Cancer Hospital of Shandong First Medical University) · 济南
- Fudan University Zhongshan Hospital · 上海
- The Second Affiliated Hospital of Soochow University · 苏州
公开的入选条件
- * Life expectancy of ≥ 12 weeks in the opinion of the investigator.
- * Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.
- * Adequate bone marrow and organ function.
- * Recovered from toxicity to prior anti-cancer therapy.
- Part 1 Dose Escalation cohort ONLY:
- * Part 1A: Advanced/metastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations
- * Part 1B: Advanced/metastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
- * Part 1C: Advanced/metastatic PDAC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05786924；登记信息更新于 2026-09-16。